Financials in USD. Standardized financial statements.
A compact view of how BioPharma Credit PLC turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $140.23M | $124.46M | $159.68M | $213.77M | $126.39M | $95.96M | $124.12M | $78.72M | $33.65M |
| Revenue Growth? | +12.7% | -22.1% | -25.3% | +69.1% | +31.7% | -22.7% | +57.7% | +133.9% | 0.0% |
| Cost of Revenue? | $25.73M | $25.57M | $25.24M | $33.90M | $15.89M | $18.65M | $27.59M | $18.56M | $0 |
| Gross Profit? | $114.50M | $124.46M | $110.49M | $184.25M | $87.97M | $77.31M | $96.53M | $60.16M | $33.65M |
| Gross Margin? | +81.7% | +100.0% | +69.2% | +86.2% | +69.6% | +80.6% | +77.8% | +76.4% | +100.0% |
| Operating Expenses? | -$15.35M | $2.28M | $2.04M | $1.93M | $3.01M | $2.22M | $1.79M | $8.57M | $6.48M |
| Operating Income? | $129.85M | $122.18M | $108.45M | $182.31M | $84.96M | $89.14M | $122.33M | $70.15M | $27.12M |
| EBITDA? | $129.89M | $122.18M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | $129.89M | $122.18M | $108.45M | $182.31M | $84.96M | $89.14M | $122.33M | $70.15M | $27.16M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$161,141 | $40,286 |
| Net Income? | $129.89M | $122.18M | $108.45M | $182.31M | $84.96M | $89.14M | $122.33M | $70.15M | $27.16M |
| EPS? | $0.11 | $0.10 | $0.08 | $0.13 | $0.06 | $0.06 | $0.09 | $0.05 | $0.04 |
| Diluted EPS? | $0.11 | $0.10 | $0.08 | $0.13 | $0.06 | $0.06 | $0.09 | $0.05 | $0.04 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality